Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma

BACKGROUND. The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC). We tested the multitargeted “chemo-switch” regimen as first-line treatment in patients with mRCC. METHODS. We assessed the maximum tolerated dose and antitumor a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bellmunt, Joaquim, Suarez, Cristina, Gallardo, Enrique, Rodon, Jordi, Pons, Francesc, Bonfill, Teresa, Beltran, Marta, Moya, Irene, Galtes, Susana, Albanell, Joan, Carles, Joan
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4153461/
https://ncbi.nlm.nih.gov/pubmed/25142843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0072
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados